|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Liver cancer:Targeted future options显示文摘Hepatocellular carcinoma(HCC)has a poor prognosis an d systemic chemotherapies have disappointing results.The increasing knowledge of the molecular biolog y of HCC has resulted in novel targets,with the vascular endothelial growth factor and epidermal growth factor receptor(EGFR)-related pathways being of special interest.New blood vessel formation(angiogenesis)is essential for the growth of solid tumors.Anti-angiogenic strategies have become an important therapeutic modality for solid tumors.Several agents targeting angiogenesis-related pathways have entered clinical trials or have been already approved for the treatment of solid tumors.These include monoclonal antibodies,receptor tyrosine kinase inhibitors and immunomodulatory drugs.HCC is a highly vascular tumor,and angiogenesis is be-lieved to play an important role in its development and progression.This review summarizes recent advances in the basic understanding of the role of angiogenesis in HCC as well as clinical trials with novel therapeutic approaches targeting angiogenesis and EGFR-related pathways. | Andreas Pircher Michael Medinger Joachim Drevs | 2011 | World Journal of Hepatology2011，3，2： | 6 |
| 2 | Effects of PTK787/ZK 222584,a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases,on primary tumor,metastasis,vessel density,and blood flow in a murine renal cell carcinoma model显示文摘 | Hofmann I Hugenschmidt H | 2000 | Cancer Res2000，60，17： | 1 |
| 3 | PTK787/ZK 222584, a speeific vascular endothelial growth factor-receptor tyrosine kinase inhibitor, affects the anatomy of the tumor vascular bed and the functional vascular properties as detected by dynamic enhanced magnetic resonance imaging显示文摘 | Drevs J Muller-Driver R Wittig C | 2002 | Cancer Res2002，1562，14： | 1 |
| 4 | Antiangiogenesis: current elinieal data and future perspectives显示文摘 | Drevs J Laus C Mendinger M | 2002 | Onkologie2002，25，6： | 1 |
| 5 | Vascular endothelial growth factor receptor tyro- sine kinase inhibitors : PTIC787/ZK 222584 显示文摘 | Thomas AL Morgan B Drevs J Unger C Wiedenmann B Van- hoefer U | 2003 | Semin Oncol2003，30，6： | 1 |
| 6 | Implications of vascular endothelial growth factor,s Flt-1,and s Tie-2 in plasma,serum and cerebrospinal fluid during cerebral ischemia in man显示文摘 | Scheufler K M Drevs J van Velthoven V | 2003 | J Cereb Blood Flow Metab2003，23，1： | 1 |
| 7 | Phase I clinical study of AZD2171, an oral vascular endothelial growth factor sig- naling inhibitor, in patients with advanced solid tumors显示文摘 | Drevs J Siegert P Medinger M | 2007 | J Clin Oncol2007，25，21： | 1 |
| 8 | Soluble markers for the detection of hypoxia under antiangiogenic treatment 显示文摘 | Drevs J | 2003 | Anticancer Research2003，23，2： | 1 |
| 9 | Antiangiogenic potency of various chemotherapeutic drugs for metronomic chemotherapy显示文摘 | DREVS J FAKLER J EISELE S | 2004 | Anticancer Res2004，24，9： | 1 |
| 10 | Phase Ⅰ clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor, in patients with liver metastases from solid tumours 显示文摘 | Mross K Drevs J Muller M | 2005 | Eur J Cancer2005，41，9： | 1 |
| 11 | Phase Ⅰ clinical study of AZD2171 ,an oral vascular endothelial growth factor signaling inhibitor,in patients with advanced solid tumors 显示文摘 | DREVS J SIEGERT P MEDINGER M | 2007 | J Clin Oncol2007，25，21： | 1 |
| 12 | Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK222584 ,an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase Ⅰ studies 显示文摘 | Morgan B Thomas AL Drevs J | 2003 | J Clin Oncol2003，21，21： | 1 |
| 13 | Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model 显示文摘 | Drevs J Hofmann I Hugenschmidt H Wittig C Madjar H Miiller M | 2000 | Cancer Res2000，60，17： | 1 |
| 14 | Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, vessel density, and blood flow in a murine renal cell careinoma model显示文摘 | Drevs J | 2000 | Cancer Res2000，60，17： | 1 |
| 15 | Phase Ⅰ clinical and pharmacokinetic study of PTK/ZK, a multiple VEGF receptor inhibitor,in patients with liver metasta- ses from solid tumors显示文摘 | Mross K Drevs J Muller M Medinger M Marine D Hennig J | 2005 | Eur J Cancer2005，41，9： | 1 |
| 16 | Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kinases, on primary tumor, metastasis, vessel density, and blood flow in a routine renal cell carcinoma model 显示文摘 | DREVS J HOFMANN I HUGENSCHMIDT H | 2000 | Cancer Research2000，60，17： | 1 |
| 17 | Phase I clinical study AZD2171, an oral vascular endothelial growth facter signaling inhibitor,in patients with advanced solid tumors显示文摘 | DREVS J SIEGERT P MEDINGER M | 2007 | J Clin Oncol2007，25，21： | 1 |
| 18 | Effects of PTK787/ZK 222584, a specific inhibitor of vascular endothelial growth factor receptor tyrosine kineses, on primary tumor, metastasis, vessel density, and blood flow in a murine renal cell carcinoma model 显示文摘 | Drevs J Hofmann I Hugenschmidt H | 2000 | Cancer Res2000，60，17： | 1 |
| 19 | Mode of action and clinical impact of VEGF sig- naling inhibitors显示文摘 | Soltau J Drevs J | 2009 | Expert Rev Anticancer Ther2009，9，： | 1 |
| 20 | Intravitreal injection of specific receptor tyrosine kinase inhibitor PTK787/ZK222 584 improves ischemia-induced retinopathy in mice显示文摘 | Maier P Unsoeld AS Junker B Martin G Drevs J Hansen LL | 2005 | Graefe Arch Clin Exp Ophthalmol2005，243，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员